Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
DMD Gene Therapy Elevidys Hits Japan Market at Record Price
Chugai Pharmaceutical on February 20 launched its Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec) in Japan at a price of nearly 305 million yen — the highest ever set under the country’s drug reimbursement system. Elevidys, Japan’s first…
To read the full story
Related Article
- Medii, Pediatric Neurology Society Build System to Support Elevidys Use
April 24, 2026
- Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause
March 10, 2026
- DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
- Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
- Elevidys Coverage Debate to Resume after MHLW Gains Broad Understanding on Safety
October 9, 2025
- MHLW Orders Label Revision for Elevidys to Add Acute Hepatic Failure
September 1, 2025
- Chugai to Defer Domestic Supply of Elevidys amid Safety Review
July 25, 2025
- Japan Puts a Hold on Coverage Discussions for Elevidys over Safety Concerns
June 19, 2025
- Chugai Halts Dosing of Non-Ambulatory Patients in DMD Gene Therapy Trial after 2 Deaths Overseas
June 17, 2025
- Chugai’s DMD Gene Therapy Snags Conditional Approval in Japan
May 14, 2025
BUSINESS
- Eisai to Raise 50 Billion Yen via Bond Issue for R&D, Licensing
June 5, 2026
- Japan Market for Fertility, Contraception, Female Disorders Put at 228.5 Billion Yen by FY2035
June 5, 2026
- Toho, DHL Partner on Healthcare Logistics Platform
June 5, 2026
- Keytruda Maintains Lead as Japan’s Top-Selling Drug for 32nd Month: Encise
June 5, 2026
- Boehringer’s Japan Pharma Sales Up for 7th Straight Year, 10-Plus Launches Eyed by 2030
June 4, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…